Allena Pharmaceuticals, Inc.

CIK:0001624658|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 3,981	$ 10,090	$ 11,739	$ 17,942
General and administrative	2,943	3,597	6,742	7,155
Total operating expenses	6,924	13,687	18,481	25,097
Loss from operations	(6,924)	(13,687)	(18,481)	(25,097)
Other income (expense):
Loss on issuance of securities	(371)		(371)
Change in valuation of warrant liability	(1,023)		(1,023)
Interest expense, net	(118)	(253)	(367)	(488)
Other income (expense), net	1	(32)	(6)	(23)
Other expense, net	(1,511)	(285)	(1,767)	(511)
Net loss	$ (8,435)	$ (13,972)	$ (20,248)	$ (25,608)
Net loss per share attributable to common stockholders-basic	$ (0.08)	$ (0.24)	$ (0.21)	$ (0.45)
Net loss per share attributable to common stockholders-diluted	$ (0.08)	$ (0.24)	$ (0.21)	$ (0.45)
Weighted-average common share outstanding-basic	100,623,730	57,932,389	95,034,212	56,484,811
Weighted-average common share outstanding-diluted	100,623,730	57,932,389	95,034,212	56,484,811
Comprehensive loss	$ (8,435)	$ (13,972)	$ (20,248)	$ (25,608)

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (20,248)	$ (25,608)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,177	1,827
Depreciation expense	243	145
Loss on issuance of securities	371
Change in valuation of warrant liability	1,023
Non-cash interest expense	52	27
Non-cash lease expense	189	190
Changes in assets and liabilities:
Prepaid expenses and other current assets	(6,879)	542
Other assets		(50)
Accounts payable	1,241	124
Accrued expenses	(1,610)	1,555
Operating lease liabilities	(153)	(150)
Net cash used in operating activities	(24,594)	(21,398)
Cash flows from investing activities:
Purchases of property and equipment		(457)
Net cash used in investing activities		(457)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of issuance costs	3,944	13,464
Proceeds from the issuance of convertible preferred stock, net of issuance costs	2,251
Proceeds from issuance of stock through ESPP		5
Repayment of loan payable	(5,000)
Net cash provided by financing activities	1,195	13,469
Net decrease in cash and cash equivalents	(23,399)	(8,386)
Cash and cash equivalents, beginning of period	29,988	35,042
Cash and cash equivalents, end of period	$ 6,589	26,656
Supplemental disclosures:
Issuance costs included in accounts payable and accrued expenses		$ 10

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 6,589	$ 29,988
Prepaid expenses and other current assets	9,897	3,018
Total current assets	16,486	33,006
Property and equipment, net	930	1,173
Operating lease assets	272	455
Other assets	123	123
Total assets	17,811	34,757
Current liabilities:
Accounts payable	2,271	1,030
Loan payable, net of discount	4,904	9,852
Accrued expenses and other current liabilities	2,870	4,480
Operating lease liabilities, net of discount	380	317
Total current liabilities	10,425	15,679
Warrant liability	3,645
Operating lease liabilities, net of current portion and discount		210
Total liabilities	14,070	15,889
Commitments and contingencies (Note 6)
Stockholders’ equity:
Undesignated preferred stock, $0.001 par value; 5,000,000 shares authorized; 2,872 shares issued and no shares outstanding at June 30, 2022; no shares issued and outstanding at December 31, 2021
Common stock, $0.001 par value; 200,000,000 shares authorized; 107,725,169 and 82,969,421 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	108	83
Additional paid-in capital	270,333	265,237
Accumulated deficit	(266,700)	(246,452)
Total stockholders’ equity	3,741	18,868
Total liabilities and stockholders’ equity	$ 17,811	$ 34,757